Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies

Stephen M. Condon, Yasuhiro Mitsuuchi, Yijun Deng, Matthew G. Laporte, Susan R. Rippin, Thomas Haimowitz, Matthew D. Alexander, Pavan Tirunahari Kumar, Mukta S. Hendi, Yu Hua Lee, Christopher A. Benetatos, Guangyao Yu, Gurpreet Singh Kapoor, Eric Neiman, Martin E. Seipel, Jennifer M. Burns, Martin A. Graham, Mark A. McKinlay, Xiaochun Li, Jiawei WangYigong Shi, Rebecca Feltham, Bodhi Bettjeman, Mathew H. Cumming, James E. Vince, Nufail Khan, John Silke, Catherine L. Day, Srinivas K. Chunduru

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently undergoing clinical development for the treatment of cancer. Using a range of assays that evaluated cIAP1 stability and oligomeric state, we demonstrated that 1 stabilized the cIAP1-BUCR (BIR3-UBA-CARD-RING) dimer and promoted autoubiquitylation of cIAP1 in vitro. Smac-mimetic 1-induced loss of cIAPs correlated with inhibition of TNF-mediated NF-κB activation, caspase activation, and tumor cell killing. Many first-generation Smac-mimetics such as compound A (2) were poorly tolerated. Notably, animals that lack functional cIAP1, cIAP2, and XIAP are not viable, and 2 mimicked features of triple IAP knockout cells in vitro. The improved tolerability of 1 was associated with (i) decreased potency against cIAP2 and affinity for XIAP BIR3 and (ii) decreased ability to inhibit XIAP-dependent signaling pathways. The P2′ position of 1 was critical to this differential activity, and this improved tolerability has allowed 1 to proceed into clinical studies.

Original languageEnglish (US)
Pages (from-to)3666-3677
Number of pages12
JournalJournal of Medicinal Chemistry
Volume57
Issue number9
DOIs
StatePublished - May 8 2014

Fingerprint

Hematologic Neoplasms
Caspases
Neoplasms
Proteins
In Vitro Techniques
birinapant
neurotensin mimic 2
Clinical Studies
altersolanol A

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Condon, S. M., Mitsuuchi, Y., Deng, Y., Laporte, M. G., Rippin, S. R., Haimowitz, T., ... Chunduru, S. K. (2014). Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. Journal of Medicinal Chemistry, 57(9), 3666-3677. https://doi.org/10.1021/jm500176w

Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. / Condon, Stephen M.; Mitsuuchi, Yasuhiro; Deng, Yijun; Laporte, Matthew G.; Rippin, Susan R.; Haimowitz, Thomas; Alexander, Matthew D.; Kumar, Pavan Tirunahari; Hendi, Mukta S.; Lee, Yu Hua; Benetatos, Christopher A.; Yu, Guangyao; Kapoor, Gurpreet Singh; Neiman, Eric; Seipel, Martin E.; Burns, Jennifer M.; Graham, Martin A.; McKinlay, Mark A.; Li, Xiaochun; Wang, Jiawei; Shi, Yigong; Feltham, Rebecca; Bettjeman, Bodhi; Cumming, Mathew H.; Vince, James E.; Khan, Nufail; Silke, John; Day, Catherine L.; Chunduru, Srinivas K.

In: Journal of Medicinal Chemistry, Vol. 57, No. 9, 08.05.2014, p. 3666-3677.

Research output: Contribution to journalArticle

Condon, SM, Mitsuuchi, Y, Deng, Y, Laporte, MG, Rippin, SR, Haimowitz, T, Alexander, MD, Kumar, PT, Hendi, MS, Lee, YH, Benetatos, CA, Yu, G, Kapoor, GS, Neiman, E, Seipel, ME, Burns, JM, Graham, MA, McKinlay, MA, Li, X, Wang, J, Shi, Y, Feltham, R, Bettjeman, B, Cumming, MH, Vince, JE, Khan, N, Silke, J, Day, CL & Chunduru, SK 2014, 'Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies', Journal of Medicinal Chemistry, vol. 57, no. 9, pp. 3666-3677. https://doi.org/10.1021/jm500176w
Condon, Stephen M. ; Mitsuuchi, Yasuhiro ; Deng, Yijun ; Laporte, Matthew G. ; Rippin, Susan R. ; Haimowitz, Thomas ; Alexander, Matthew D. ; Kumar, Pavan Tirunahari ; Hendi, Mukta S. ; Lee, Yu Hua ; Benetatos, Christopher A. ; Yu, Guangyao ; Kapoor, Gurpreet Singh ; Neiman, Eric ; Seipel, Martin E. ; Burns, Jennifer M. ; Graham, Martin A. ; McKinlay, Mark A. ; Li, Xiaochun ; Wang, Jiawei ; Shi, Yigong ; Feltham, Rebecca ; Bettjeman, Bodhi ; Cumming, Mathew H. ; Vince, James E. ; Khan, Nufail ; Silke, John ; Day, Catherine L. ; Chunduru, Srinivas K. / Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. In: Journal of Medicinal Chemistry. 2014 ; Vol. 57, No. 9. pp. 3666-3677.
@article{5547770311ea4c999e0e651d39277b52,
title = "Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies",
abstract = "Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently undergoing clinical development for the treatment of cancer. Using a range of assays that evaluated cIAP1 stability and oligomeric state, we demonstrated that 1 stabilized the cIAP1-BUCR (BIR3-UBA-CARD-RING) dimer and promoted autoubiquitylation of cIAP1 in vitro. Smac-mimetic 1-induced loss of cIAPs correlated with inhibition of TNF-mediated NF-κB activation, caspase activation, and tumor cell killing. Many first-generation Smac-mimetics such as compound A (2) were poorly tolerated. Notably, animals that lack functional cIAP1, cIAP2, and XIAP are not viable, and 2 mimicked features of triple IAP knockout cells in vitro. The improved tolerability of 1 was associated with (i) decreased potency against cIAP2 and affinity for XIAP BIR3 and (ii) decreased ability to inhibit XIAP-dependent signaling pathways. The P2′ position of 1 was critical to this differential activity, and this improved tolerability has allowed 1 to proceed into clinical studies.",
author = "Condon, {Stephen M.} and Yasuhiro Mitsuuchi and Yijun Deng and Laporte, {Matthew G.} and Rippin, {Susan R.} and Thomas Haimowitz and Alexander, {Matthew D.} and Kumar, {Pavan Tirunahari} and Hendi, {Mukta S.} and Lee, {Yu Hua} and Benetatos, {Christopher A.} and Guangyao Yu and Kapoor, {Gurpreet Singh} and Eric Neiman and Seipel, {Martin E.} and Burns, {Jennifer M.} and Graham, {Martin A.} and McKinlay, {Mark A.} and Xiaochun Li and Jiawei Wang and Yigong Shi and Rebecca Feltham and Bodhi Bettjeman and Cumming, {Mathew H.} and Vince, {James E.} and Nufail Khan and John Silke and Day, {Catherine L.} and Chunduru, {Srinivas K.}",
year = "2014",
month = "5",
day = "8",
doi = "10.1021/jm500176w",
language = "English (US)",
volume = "57",
pages = "3666--3677",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies

AU - Condon, Stephen M.

AU - Mitsuuchi, Yasuhiro

AU - Deng, Yijun

AU - Laporte, Matthew G.

AU - Rippin, Susan R.

AU - Haimowitz, Thomas

AU - Alexander, Matthew D.

AU - Kumar, Pavan Tirunahari

AU - Hendi, Mukta S.

AU - Lee, Yu Hua

AU - Benetatos, Christopher A.

AU - Yu, Guangyao

AU - Kapoor, Gurpreet Singh

AU - Neiman, Eric

AU - Seipel, Martin E.

AU - Burns, Jennifer M.

AU - Graham, Martin A.

AU - McKinlay, Mark A.

AU - Li, Xiaochun

AU - Wang, Jiawei

AU - Shi, Yigong

AU - Feltham, Rebecca

AU - Bettjeman, Bodhi

AU - Cumming, Mathew H.

AU - Vince, James E.

AU - Khan, Nufail

AU - Silke, John

AU - Day, Catherine L.

AU - Chunduru, Srinivas K.

PY - 2014/5/8

Y1 - 2014/5/8

N2 - Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently undergoing clinical development for the treatment of cancer. Using a range of assays that evaluated cIAP1 stability and oligomeric state, we demonstrated that 1 stabilized the cIAP1-BUCR (BIR3-UBA-CARD-RING) dimer and promoted autoubiquitylation of cIAP1 in vitro. Smac-mimetic 1-induced loss of cIAPs correlated with inhibition of TNF-mediated NF-κB activation, caspase activation, and tumor cell killing. Many first-generation Smac-mimetics such as compound A (2) were poorly tolerated. Notably, animals that lack functional cIAP1, cIAP2, and XIAP are not viable, and 2 mimicked features of triple IAP knockout cells in vitro. The improved tolerability of 1 was associated with (i) decreased potency against cIAP2 and affinity for XIAP BIR3 and (ii) decreased ability to inhibit XIAP-dependent signaling pathways. The P2′ position of 1 was critical to this differential activity, and this improved tolerability has allowed 1 to proceed into clinical studies.

AB - Birinapant (1) is a second-generation bivalent antagonist of IAP proteins that is currently undergoing clinical development for the treatment of cancer. Using a range of assays that evaluated cIAP1 stability and oligomeric state, we demonstrated that 1 stabilized the cIAP1-BUCR (BIR3-UBA-CARD-RING) dimer and promoted autoubiquitylation of cIAP1 in vitro. Smac-mimetic 1-induced loss of cIAPs correlated with inhibition of TNF-mediated NF-κB activation, caspase activation, and tumor cell killing. Many first-generation Smac-mimetics such as compound A (2) were poorly tolerated. Notably, animals that lack functional cIAP1, cIAP2, and XIAP are not viable, and 2 mimicked features of triple IAP knockout cells in vitro. The improved tolerability of 1 was associated with (i) decreased potency against cIAP2 and affinity for XIAP BIR3 and (ii) decreased ability to inhibit XIAP-dependent signaling pathways. The P2′ position of 1 was critical to this differential activity, and this improved tolerability has allowed 1 to proceed into clinical studies.

UR - http://www.scopus.com/inward/record.url?scp=84900308237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900308237&partnerID=8YFLogxK

U2 - 10.1021/jm500176w

DO - 10.1021/jm500176w

M3 - Article

C2 - 24684347

AN - SCOPUS:84900308237

VL - 57

SP - 3666

EP - 3677

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 9

ER -